EtG 300 vs 500 ng/mL cutoff: which threshold fits your program?

Who this guide is for and what it covers

If you administer alcohol testing for a sober-living program, probation caseload, clinical treatment facility, or workplace, the cutoff level printed on your EtG test strip is one of the most consequential decisions you can make. Set it too high and you miss real relapse events. Set it too low and you risk flagging incidental ethanol exposure from mouthwash or hand sanitizer, damaging the trust your program depends on.

This article compares the two cutoff concentrations most commonly offered on point-of-care immunoassay EtG urine tests: 300 ng/mL and 500 ng/mL. It explains what each number means, who each threshold serves, what verification questions to ask a supplier, and how to match the cutoff to your program's risk tolerance and documentation requirements.

What this article does NOT cover:

• Breath alcohol testing (EtG is a urine metabolite marker, not a breathalyzer analyte)
• Laboratory GC-MS confirmation methodology
• Named commercial EtG products compared against each other on performance specifications
• Blood or hair EtG matrices

What EtG is and why the cutoff matters

Ethyl glucuronide (EtG) is a direct, minor metabolite of ethanol produced in the liver. Because it can be detected in urine long after breath alcohol returns to zero, it became the standard biomarker for abstinence-based monitoring programs that need a longer detection window than a standard urine ethanol test provides.

The cutoff concentration is the threshold above which a test reports a presumptive positive. Below that concentration, the strip reports negative — regardless of whether any EtG is technically present. This is by design: immunoassay screening strips are engineered to a specific cutoff, not to detect the absolute lowest possible concentration.

Two facts frame the entire 300-vs-500 debate:

1. Higher cutoff = less sensitive — A 500 ng/mL strip will not flag a specimen that contains 350 ng/mL of EtG. A 300 ng/mL strip will.
2. Lower cutoff = more sensitive — But sensitivity cuts both ways: incidental ethanol exposures (certain foods, medications, hygiene products) that produce low-level EtG excretion become more likely to be flagged at 300 ng/mL.

Everything downstream — false positive rates, detection windows, program defensibility, and client relationships — flows from that trade-off.

Quick-reference comparison table

Important: Detection windows for EtG vary substantially by individual metabolic rate, body weight, hydration status, dose consumed, frequency of use, and the specific cutoff used. No detection-window figure should be treated as a guarantee. Always verify the claimed detection window with your supplier and confirm it against the package insert.

Detailed analysis: 300 ng/mL EtG cutoff

What it is

A 300 ng/mL EtG test will report presumptive positive on any specimen where EtG concentration meets or exceeds 300 nanograms per milliliter at the time of collection.

Pros

• Greater detection sensitivity. Light or infrequent alcohol consumption events, or specimens collected later in the elimination window, are more likely to be captured at 300 ng/mL than at 500 ng/mL.
• Longer effective monitoring window. For the same drinking event, EtG concentrations decline over time; a lower cutoff means the specimen remains above threshold for a longer post-drinking interval.
• Appropriate for intensive compliance programs. Court-mandated zero-tolerance conditions, residential treatment monitoring, and sober-living house contracts often require the highest clinically defensible sensitivity. The 300 ng/mL threshold supports a more rigorous monitoring stance.
• Detects heavier hedging strategies. Individuals who have learned to time their drinking to avoid detection around testing windows have less margin at 300 ng/mL.

Cons

• Elevated incidental exposure risk. Certain foods prepared with vanilla extract, ripe fruits that have undergone fermentation, some over-the-counter medications, and certain oral hygiene products contain trace ethanol that can produce low-level EtG excretion — potentially enough to cross a 300 ng/mL threshold. The scientific and clinical literature has discussed this; ask your supplier for their technical data on incidental exposure ranges.
• Higher confirmation testing volume. If your policy requires lab confirmation (GC-MS) of all non-negatives before adverse action, a 300 ng/mL threshold will generate more specimens requiring send-out, increasing cost and turnaround time.
• Requires a clear incidental-exposure policy. Without a documented policy that addresses how low-level positives will be handled, a 300 ng/mL result is harder to act on in a formal proceeding.

Best-fit use cases

• Residential substance use treatment programs
• Sober-living house monitoring (high-frequency, close supervision)
• Probation and parole zero-tolerance conditions
• Drug court programs with contractual abstinence requirements
• Pain management and methadone clinic compliance monitoring

What to verify with your supplier

• What is the claimed detection window at 300 ng/mL, and what assumptions does it rest on?
• Does the package insert include data on cross-reactivity with non-alcoholic ethanol sources?
• Is the test designated CLIA Waived, 510(k) cleared, E&I, or FUO? (Each designation has implications for where and by whom it can be used — see the regulatory designations reference above.)
• What confirmation methodology does the supplier or their reference lab use for non-negatives?

Detailed analysis: 500 ng/mL EtG cutoff

What it is

A 500 ng/mL EtG test will report presumptive positive only when EtG concentration meets or exceeds 500 nanograms per milliliter. Specimens containing EtG below that level report negative.

Pros

• Reduced incidental exposure risk. The clinical literature widely discussed that incidental exposure from non-beverage sources rarely produces EtG concentrations exceeding 500 ng/mL, though this should be confirmed against current research; ask your supplier for supporting data. For programs that cannot afford an incidental-exposure controversy, 500 ng/mL provides a more defensible floor.
• SAMHSA-referenced threshold. The Substance Abuse and Mental Health Services Administration has cited 500 ng/mL as a reporting cutoff reference point in its guidance for workplace programs. Verify whether current guidance applies to your program type before selecting based on this criterion alone.
• Lower confirmation volume. Programs that require lab confirmation of non-negatives will send fewer specimens to an external laboratory, reducing cost and administrative burden.
• Easier to defend without specialized policy. If a tested individual challenges a result, the 500 ng/mL threshold is more broadly recognized in professional guidance documents, making defense of the cutoff choice more straightforward.

Cons

• Narrower detection window. Specimens collected later in the elimination window following a drinking event may fall below 500 ng/mL while still containing EtG — meaning a genuine abstinence violation could be missed.
• Reduced sensitivity for light drinking events. A single low-dose alcohol consumption event may produce peak EtG concentrations that cross 300 ng/mL but not 500 ng/mL, depending on individual physiology.
• Less deterrent value in high-compliance programs. Individuals who are aware of cutoff levels and testing schedules may calculate that a 500 ng/mL threshold gives them more room to consume alcohol without detection.

Best-fit use cases

• Workplace pre-employment and random alcohol monitoring
• Staffing agency compliance programs
• Lower-frequency screening programs (weekly or less frequent)
• Programs where incidental exposure controversy carries significant reputational or legal risk
• DOT-adjacent programs that reference SAMHSA guidance (verify applicability to your specific context)

What to verify with your supplier

• Does the package insert or technical data sheet state the specific cutoff as 500 ng/mL, or does the product description use a rounded or approximated figure?
• What is the coefficient of variation at the cutoff concentration, and how does that affect borderline specimen reporting?
• Is the product currently CLIA Waived, 510(k) cleared, E&I, or FUO? Verify the current regulatory status directly, as designations can change.
• What is the supplier's recommended hold time and temperature for EtG specimens between collection and testing?

The incidental exposure controversy: what program administrators need to know

The debate over incidental exposure and EtG is one of the most frequently cited reasons for the 300-vs-500 disagreement in the clinical community. The core question: can non-drinking ethanol sources produce enough EtG to trigger a positive on a screening test?

Key points for administrators:

• Source matters. Hand sanitizers, mouthwash containing alcohol, certain fermented foods, and some medications have been discussed as potential contributors to low-level EtG excretion. The concentrations produced vary and depend on amount used, frequency, and individual metabolism.
• Concentration thresholds matter. Clinical guidance has generally treated concentrations below 500 ng/mL as a zone where incidental exposure cannot be definitively ruled out. Above 1,000 ng/mL, voluntary alcohol consumption becomes the far more likely explanation. The 300–500 ng/mL range is the most contested zone.
• Your policy determines outcome, not the test strip alone. The strip gives you a number; your written policy governs what happens next. Before selecting a cutoff, document:
  • Whether confirmation testing is required before adverse action
  • How the program handles borderline or contested results
  • What products (mouthwash, hand sanitizer, medication) tested individuals are instructed to avoid
  • Whether a Medical Review Officer (MRO) is involved in result interpretation

Without a written policy, neither cutoff is fully defensible in a formal proceeding.

The role of testing frequency in cutoff selection

Cutoff level and testing frequency are inseparable decisions. Understand the interaction:

• High-frequency testing (daily or every-other-day): The shorter detection window of a 500 ng/mL test matters less when specimens are collected frequently. Even if a specimen collected 60+ hours after a drinking event falls below 500 ng/mL, the next collection is only a day away. High frequency partially compensates for a less sensitive cutoff.
• Low-frequency testing (weekly or less): If testing happens once a week, a 500 ng/mL threshold leaves a longer period during which EtG concentrations may have declined below the threshold following a mid-week drinking event. In low-frequency programs, 300 ng/mL extends the detectable window and reduces the gap.
• Random testing: The unpredictability of collection timing is itself a deterrent, but pairing random testing with a 300 ng/mL threshold closes gaps further.

How to choose: buying considerations for program administrators

Step 1: Define the program goal

Is the goal absolute abstinence verification (treatment, drug court, sober living) or deterrence and general compliance (workplace, staffing)? Abstinence programs typically benefit from 300 ng/mL. Compliance programs often find 500 ng/mL sufficient.

Step 2: Assess your confirmation workflow

Do you send non-negatives to a laboratory for GC-MS confirmation before taking adverse action? If yes, confirm the lab's reporting threshold. Some labs apply their own cutoff that may differ from the screening cutoff. Clarify the chain-of-custody implications with your supplier and reference lab.

Step 3: Review any applicable guidance documents

Federal workplace programs (DOT-regulated industries) and SAMHSA-certified labs operate under specific cutoff rules. Non-regulated programs have more flexibility, but referencing SAMHSA guidance or your state's relevant health department guidelines is best practice. Verify applicable guidance before locking in a cutoff.

Step 4: Write your incidental exposure policy first

Before purchasing, draft the policy that governs what happens when a result falls in the 300–500 ng/mL range. This affects which cutoff makes sense for your documentation obligations and risk tolerance.

Step 5: Verify the regulatory designation of the test

Check whether the product is CLIA Waived, 510(k) cleared, E&I, or FUO. Each designation restricts or enables specific use environments. A test used outside its designated context creates compliance exposure. Refer to the regulatory designations reference section for guidance on what each designation means in practice.

Step 6: Ask the supplier these specific questions

• What is the exact cutoff stated on the package insert?
• What is the analytical sensitivity (lowest detectable concentration)?
• What is the cross-reactivity profile for common incidental ethanol sources?
• What is the shelf life and storage requirement? (Verify on the package insert.)
• Is the cutoff configurable or fixed for this SKU?

Step 7: Pilot before committing at volume

If you are switching cutoffs or adopting EtG testing for the first time, pilot a smaller quantity before placing a large order. Evaluate the confirmation rate and any contested results before scaling.

Closing recommendation

There is no universally correct answer between 300 ng/mL and 500 ng/mL. The right choice is determined by program type, testing frequency, confirmation workflow, and the written policy your program maintains.

Use 300 ng/mL when: your program demands strict abstinence verification, testing frequency is lower than daily, you have a confirmation pathway and an incidental-exposure policy in place, and your client population includes individuals with history of attempting to game detection windows.

Use 500 ng/mL when: your primary goal is deterrence rather than absolute abstinence verification, your program faces meaningful incidental exposure risk (for example, certain healthcare or food-service workforces), you lack the infrastructure for high-volume confirmation testing, or your program references SAMHSA workplace guidance.

In either case, pair the cutoff decision with a written policy, a clear confirmation pathway, and transparent communication with those being tested about what products to avoid. The strip is a tool; the program design determines its effectiveness.